Genital Chlamydia infections have increased over 4-fold in the last decade. Untreated infections lead to pelvic inflammatory disease, ectopic pregnancy and infertility. These conditions are due to the inflammatory immune response elicited by infections that cause scarring and oviduct blockage. The proposed studies will determine how the immune system causes tissue damage and how this damage can be avoided to enable the development a vaccine that protects women against infection and infertility.
Antibiotic Treatment Of Male Partners To Reduce Recurrence Of Bacterial Vaginosis In Women: A Randomised Double-blind Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$636,674.00
Summary
Bacterial vaginosis (BV) is the most common vaginal infection in women. Healthy bacteria are lost and replaced by bacteria that cause unpleasant discharge and odour. BV puts women at increased risk of sexually transmitted infections, HIV, miscarriage and preterm delivery. Over 50% of women given antibiotics get BV back again. Studies suggest these bacteria are being sexually transmitted. We are conducting a trial of antibiotic treatment of women and their male partners to improve BV cure.
Systematic Investigation Of Conceivable Mechanisms That Could Lead To False Positive Diagnoses Of Sexually Transmitted Infections In Young Children.
Funder
National Health and Medical Research Council
Funding Amount
$1,008,839.00
Summary
Diagnosis of a sexually transmitted infection (STI) in a young child has serious social and legal consequences, because it is usually regarded as indicative of sexual abuse. It is therefore critical to understand the probability of such a diagnosis in the absence of sexual abuse. We will investigate false positives that arise by contamination of the urogenital site by STI agents that also infect the eye, and the transfer of contaminants from fingers to diagnostic specimens.
Investigation Of Candidate Aetiologic Organisms Of Bacterial Vaginosis In Diverse And Unique Epidemiological And Clinical Studies
Funder
National Health and Medical Research Council
Funding Amount
$564,438.00
Summary
Bacterial vaginosis (BV), a vaginal infection affecting 10% of Australian women, is an important cause of premature birth, yet its cause is unknown. We are conducting studies to understand the cause of BV in order to improve diagnosis and treatment.
Evaluation Of Chlamydia Trachomatis Treatment Failure: A Cohort Study Of Women
Funder
National Health and Medical Research Council
Funding Amount
$761,844.00
Summary
Chlamydia is a very common sexually transmissible infection in Australia that can lead to infertility in women. About 4% of young adults have it. There is increasing concern by experts about the efficacy of the recommended chlamydia treatment. This is further supported by very high repeat infection rates following a previous positive chlamydia diagnosis. This study will measure whether chlamydia treatment failure is a problem and if so, this will change treatment guidelines worldwide.
Mechanisms And Utilisation Of IFN-epsilon-mediated Protection Against Chlamydia Reproductive Tract Infection
Funder
National Health and Medical Research Council
Funding Amount
$750,486.00
Summary
Chlamydia is a common cause of sexually transmitted diseases resulting in pelvic inflammatory disease, infertility and ectopic pregnancy. There are no vaccines that prevent infection or disease. We have discovered a new factor in the immune system (interferon-epsilon) that only occurs in the reproductive tract. If this factor is absent then Chlamydia infections are more severe. We will investigate how this factor protects against infection and if we can use it as a new agent against Chlamydia ST ....Chlamydia is a common cause of sexually transmitted diseases resulting in pelvic inflammatory disease, infertility and ectopic pregnancy. There are no vaccines that prevent infection or disease. We have discovered a new factor in the immune system (interferon-epsilon) that only occurs in the reproductive tract. If this factor is absent then Chlamydia infections are more severe. We will investigate how this factor protects against infection and if we can use it as a new agent against Chlamydia STDs.Read moreRead less
A Novel Reproductive Tract Factor That Protects Against Chlamydia
Funder
National Health and Medical Research Council
Funding Amount
$541,133.00
Summary
Chlamydia is a common cause of sexually transmitted diseases resulting in pelvic inflammatory disease, infertility and ectopic pregnancy. There are no vaccines that prevent infection or disease. We have discovered a new factor in the immune system (interferon-epsilon) that only occurs in the reproductive tract. If this factor is absent then Chlamydia infections are more severe. We will investigate how this factor protects against infection and if we can use it as a new agent against Chlamydia ST ....Chlamydia is a common cause of sexually transmitted diseases resulting in pelvic inflammatory disease, infertility and ectopic pregnancy. There are no vaccines that prevent infection or disease. We have discovered a new factor in the immune system (interferon-epsilon) that only occurs in the reproductive tract. If this factor is absent then Chlamydia infections are more severe. We will investigate how this factor protects against infection and if we can use it as a new agent against Chlamydia STDs.Read moreRead less
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
Use Of Molecular Resistance Assays To Provide Alterative Oral Treatment Strategies For Gonorrhoea In Indigenous And Other High-risk Populations; A Randomised Cluster Trial
Funder
National Health and Medical Research Council
Funding Amount
$828,671.00
Summary
Gonorrhoea has now developed resistance to almost all antibiotics that have been used to treat it. In this study, we will investigate a new treatment approach that selects antibiotics on a patient-by-patient basis. We will use new molecular assays to first test if a gonorrhoea strain infecting a patient is susceptible to an antibiotic, and will then treat on the basis of this result. By doing so, we will optimize our use of antibiotics and improve treatment strategies for gonorrhea.
PH-dependent, Antibody-mediated Enhancement Of Genital Chlamydial Infection: Implications For Vaccine Design ?
Funder
National Health and Medical Research Council
Funding Amount
$373,228.00
Summary
Antibody found in cervicovaginal secretions is predominantly of the IgG subclass. In the acidic environment of the female reproductive tract IgG antibodies against surface antigens on Chlamydia may actually enhance rather than prevent infection, due to uptake of IgG-coated bacteria by the neonatal Fc receptor (FcRn), which is found on the surface of epithelial cells in the reproductive tract. The proposed studies will determine the effects of chlamydial antibodies on the course of infection.